Home / CXCL5/ENA-78 / Human CXCL5/ENA-78 Antibody

Human CXCL5/ENA-78 Antibody

Catalog #: AF254
10 Citations 2 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
AF254
AF254-SP
Detection of Human CXCL5/ENA‑78 by Western Blot.
4 Images
Product Details
Citations (10)
FAQs
Supplemental Products
Reviews (2)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL5/ENA-78 Antibody Summary

Species Reactivity
Human
Specificity
Detects human CXCL5/ENA‑78 in direct ELISAs and Western blots.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human CXCL5/ENA-78
Ala37-Asn114
Accession # P42830
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize CXCL5/ENA‑78-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR2. The Neutralization Dose (ND50) is typically 0.2-1.0 µg/mL in the presence of 0.03 µg/mL Recombinant Human CXCL5/ENA‑78.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human CXCL5/ENA-78 antibody by Western Blot. View Larger

Detection of Human CXCL5/ENA‑78 by Western Blot. Western blot shows conditioned media (CM) and lysates from A549 human lung carcinoma cell line untreated (-) or treated (+) with human IL-1 beta for 24 hours. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human CXCL5/ENA-78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF109). A specific band was detected for CXCL5/ENA-78 at approximately 10 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry CXCL5/ENA-78 antibody in Human Breast Cancer Tissue by Immunohistochemistry (IHC-P). View Larger

CXCL5/ENA‑78 in Human Breast Cancer Tissue. CXCL5/ENA-78 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human CXCL5/ENA-78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; (CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Immunohistochemistry CXCL5/ENA-78 antibody in Human Breast by Immunohistochemistry (IHC-P). View Larger

CXCL5/ENA‑78 in Human Breast. CXCL5/ENA-78 was detected in immersion fixed paraffin-embedded sections of human breast using Goat Anti-Human CXCL5/ENA-78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; (CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Neutralization Chemotaxis Induced by CXCL5/ENA‑78 and Neutralization by Human CXCL5/ENA‑78 Antibody. View Larger

Chemotaxis Induced by CXCL5/ENA‑78 and Neutralization by Human CXCL5/ENA‑78 Antibody. Recombinant Human CXCL5/ENA-78 (254-XB) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (AR002). Chemotaxis elicited by Recombinant Human CXCL5/ENA-78 (0.03 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL5/ENA-78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254). The ND50 is typically 0.2-1.0 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL5/ENA-78

CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR-CXC chemokines which are angiostatic (1‑3). Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP-2 and
35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP-2, and CXCL8/IL-8. Inflammatory stimulation up-regulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis (3-6). Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers (6-9). Full length CXCL5 (78 aa) is trimmed at the N-terminus by cathepsin G and chymotrypsin to ENA-74 (74 aa) and ENA-70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5 (10, 11). CXCL5 exerts its effects primarily through interactions with CXCR2 (6, 12). It also binds duffy antigen receptor for chemokines (DARC), which can limit CXCR2-mediated responses (13, 14).

References
  1. Strieter, R.M. et al. (2005) Cytokine Growth Factor Rev. 16:593.
  2. Balestrieri, M.L. et al. (2008) Cardiovasc. Res. 78:250.
  3. Walz, A.. et al. (1991) J. Exp. Med. 174:1355.
  4. Strieter, R.M. et al. (1992) Immunol. Invest. 21:549.
  5. Koch, A.E. et al. (1994) J. Clin. Invest. 94:1012.
  6. Begley, L.A. et al. (2008) Neoplasia 10:244.
  7. Vandercappellen, J. et al. (2008) Cancer Lett. 267:226.
  8. Arenberg, D.A. et al. (1998) J. Clin. Invest. 102:465.
  9. Miyazaki, H. et al. (2006) Cancer Res. 66:4279.
  10. Wuyts, A. et al. (1999) Eur. J. Biochem. 260:421.
  11. Nufer, O. et al. (1999) Biochemistry 38:636.
  12. Ahuja, S.K. and P.M. Murphy (1996) J. Biol. Chem. 271:20545.
  13. Kashiwazaki, M. et al. (2003) Int. Immunol. 15:1219.
  14. Horton, L.W. et al. (2007) Cancer Res. 67:9791.
Entrez Gene IDs
6374 (Human)
Alternate Names
chemokine (C-C motif) ligand 5; C-X-C motif chemokine 5; CXCL5; CXCL5/ENA-78; ENA78; ENA-78; ENA-78(1-78); Epithelial-derived neutrophil-activating protein 78; Neutrophil-activating peptide ENA-78; neutrophil-activating protein 78; SCYB5ENA78

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human CXCL5/ENA-78 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

10 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Tumor-Infiltrating Neutrophils after Neoadjuvant Therapy are Associated with Poor Prognosis in Esophageal Cancer
    Authors: Carlos S. Cabalag, Owen W. J. Prall, John Ciciulla, Laurence A. Galea, Niko Thio, Madawa Jayawardana et al.
    Annals of Surgical Oncology
  2. Novel adherent CD11b+Gr-1+tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment
    Authors: T Tsubaki, T Kadonosono, S Sakurai, T Shiozawa, T Goto, S Sakai, T Kuchimaru, T Sakamoto, H Watanabe, G Kondoh, S Kizaka-Kon
    Oncotarget, 2018-01-29;9(13):11209-11226.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Neutrophil infiltration mediated by CXCL5 accumulation in the laryngeal squamous cell carcinoma microenvironment: A mechanism by which tumour cells escape immune surveillance
    Authors: Li-Ming Lu
    Clin. Immunol., 2016-11-19;175(0):34-40.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  4. Chemokine CCL15 Mediates Migration of Human Bone Marrow-Derived Mesenchymal Stem Cells Toward Hepatocellular Carcinoma.
    Authors: Gao Y, Zhou Z, Lu S, Huang X, Zhang C, Jiang R, Yao A, Sun B, Wang X
    Stem Cells, 2016-01-13;34(4):1112-22.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  5. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta.
    Authors: Jablonska J, Wu C, Andzinski L, Leschner S, Weiss S
    Int J Cancer, 2013-10-31;134(6):1346-58.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  6. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
    Authors: Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ
    Am. J. Pathol., 2011-03-01;178(3):1340-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  7. A CXCL5- and bFGF-dependent effect of PDGF-B-activated fibroblasts in promoting trafficking and differentiation of bone marrow-derived mesenchymal stem cells.
    Authors: Nedeau AE, Bauer RJ, Gallagher K, Chen H, Liu ZJ, Velazquez OC
    Exp. Cell Res., 2008-04-25;314(11):2176-86.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Neutralization
  8. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients.
    Authors: Dimberg J, Dienus O, Lofgren S, Hugander A, Wagsater D
    Int. J. Oncol., 2007-07-01;31(1):97-102.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  9. Imbalance in the expression of CXC chemokines correlates with bronchoalveolar lavage fluid angiogenic activity and procollagen levels in acute respiratory distress syndrome.
    Authors: Keane MP, Donnelly SC, Belperio JA, Goodman RB, Dy M, Burdick MD, Fishbein MC, Strieter RM
    J. Immunol., 2002-12-01;169(11):6515-21.
    Species: Human
    Sample Types: BALF, Whole Tissue
    Applications: ELISA Development, IHC-P
  10. CCL20/CCR6 expression profile in pancreatic cancer
    Authors: Claudia Rubie, Vilma Oliveira Frick, Pirus Ghadjar, Mathias Wagner, Henner Grimm, Benjamin Vicinus et al.
    Journal of Translational Medicine

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human CXCL5/ENA-78 Antibody

Average Rating: 4.5 (Based on 2 Reviews)

5 Star
50%
4 Star
50%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human CXCL5/ENA-78 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human CXCL5/ENA-78 Antibody
By Anonymous on 02/18/2019
Application: WB Sample Tested: Hep3B human hepatocellular carcinoma cell line,SK-HEP-1 human liver adenocarcinoma cell line Species: Human
Western Blot Human CXCL5/ENA-78 Antibody AF254
Human CXCL5/ENA-78 Antibody
By Anonymous on 10/17/2018
Application: IHC Sample Tested: Cancer Tissue Species: Human
Immunohistochemistry Human CXCL5/ENA-78 Antibody AF254